Provention Bio, Inc. (PRVB)
| Market Cap | 430.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -118.44M |
| Shares Out | 62.26M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $6.75 |
| Previous Close | $6.80 |
| Change ($) | -0.05 |
| Change (%) | -0.74% |
| Day's Open | 6.81 |
| Day's Range | 6.55 - 6.93 |
| Day's Volume | 570,371 |
| 52-Week Range | 6.14 - 20.05 |
RED BANK, N.J., May 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial re...
RED BANK, N.J., May 3, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today anno...
RED BANK, N.J., April 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it ...
RED BANK, N.J., April 27, 2021 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the Com...
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). Such investo...
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a cel...
Provention Bio Inc (NASDAQ: PRVB) revealed it had received a notification on April 2 from the FDA stating that the agency has identified deficiencies that preclude discussion of labeling and post-market...
RED BANK, N.J., April 8, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the ...
Provention Bio (PRVB) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
RED BANK, N.J., March 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that mana...
Provention Bio Inc (NASDAQ: PRVB) is making its way into China with a new deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and CD79B, ...
RED BANK, N.J., Feb. 18, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it w...
RED BANK, N.J., Feb. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, and Hangzhou Zhongmei Hu...
These drugmakers could double your money this year.
BILTHOVEN, Netherlands, Jan. 19, 2021 /PRNewswire/ -- Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievi...
RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pric...
RED BANK, N.J., Jan. 12, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it ...
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2021 in wha...
RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that manag...
RED BANK, N.J., Jan. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the B...
RED BANK, N.J., Dec. 21, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it h...
RED BANK, N.J., Dec. 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initi...
RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that managemen...
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript
RED BANK, N.J., Nov. 5, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported financial result...
Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rolling BLA subm...
RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completion ...
RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will r...
RED BANK, N.J., Oct. 1, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national ef...
RED BANK, N.J., Sept. 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the subm...
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc.
OLDWICK, N.J., Aug. 31, 2020 /PRNewswire/ -- Provention Bio, Inc.
Under looked biotech company might be near tipping point
Each of these companies has the potential to generate life-changing returns.
OLDWICK, N.J., Aug. 11, 2020 /PRNewswire/ -- Provention Bio, Inc.
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2020 Results - Earnings Call Transcript
OLDWICK, N.J., Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc.
Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon
Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon
Provention Bio is developing a drug that could delay the onset of diabetes, and if it's successful, the company's stock could soar.
OLDWICK, N.J., June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change...
OLDWICK, N.J., June 22, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the clos...
OLDWICK, N.J., June 17, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pric...
The company announced a public offering of common stock.
OLDWICK, N.J., June 16, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it ...
Provention Bio (PRVB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The company released positive data from a clinical trial for one of its pipeline candidates.
The company released positive data from a clinical trial for one of its pipeline candidates.
About PRVB
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treat... [Read more...]
| Industry Biotechnology | |
| CEO Ashleigh Palmer | Employees 59 |
| Stock Exchange NASDAQ | Ticker Symbol PRVB |
Analyst Forecasts
According to 6 analysts, the average rating for Provention Bio stock is "Strong Buy." The 12-month stock price forecast is 18.21, which is an increase of 169.78% from the latest price.